Introduction and Pathophysiology
Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic stem cell disorders characterized by:
- Ineffective hematopoiesis, leading to persistent peripheral blood cytopenias (anemia, neutropenia, thrombocytopenia),
- Dysplasia in one or more myeloid lineages (≥10% dysplastic cells in ≥1 lineage in bone marrow),
- Hypercellular or normocellular bone marrow, and
- Increased risk of transformation to acute myeloid leukemia (AML) (approx. 30% of patients over time).
The pathogenesis involves somatic mutations in genes regulating splicing (SF3B1, SRSF2, U2AF1), DNA methylation (DNMT3A, TET2, IDH1/2), chromatin modification (EZH2), transcription (RUNX1), signal transduction (NRAS, KRAS, CBL), and cohesion complex (RAD21, STAG2). These mutations drive genomic instability, impaired differentiation, and clonal expansion. Notably, SF3B1 mutations are strongly associated with ring sideroblasts and favorable prognosis in lower-risk MDS (WHO-HAEM5 classification, 2022).
Diagnostic Evaluation: A Multimodal, Guideline-Driven Approach
1. Initial Suspicion & Workup
Suspect MDS in patients presenting with:
- Unexplained, persistent cytopenias (Hb <10 g/dL, ANC <1.8 × 10⁹/L, or platelets <100 × 10⁹/L),
- Macrocytosis (MCV >100 fL) without B₁₂/folate deficiency,
- Hypogranular neutrophils, pseudo-Pelger–Hüet anomaly, or abnormal platelet morphology,
- Bone marrow hypercellularity with dysplasia.
Essential initial workup (per NCCN v.2024, ELN 2021, and IWG-MDS 2022 criteria):
| Test | Rationale & Clinical Utility |
|---|---|
| CBC with differential + reticulocyte count | Differentiates true cytopenias from pseudocytopenias (e.g., EDTA-induced agglutination); low reticulocytes confirm ineffective erythropoiesis. |
| Peripheral blood smear review by experienced morphologist | Critical for identifying dysplastic features (e.g., hypogranular neutrophils, bicuspid platelets, nuclear bridging in erythroblasts). |
| Serum EPO level | Guides use of erythropoiesis-stimulating agents (ESAs): low EPO (<500 U/L) predicts higher ESA response in lower-risk MDS (IPSS-R very low/low; NCCN recommendation Grade 2A). |
| Vitamin B₁₂, folate, iron studies (ferritin, TIBC), viral serologies (HIV, HTLV-1), and paroxysmal nocturnal hemoglobinuria (PNH) clone screen | Exclude nutritional, autoimmune, infectious, and clonal mimics. |
| Cytogenetics (G-banding) | Detects constitutional abnormalities; key for IPSS-R scoring. Common findings: del(5q), -7/del(7q), +8, del(20q), complex karyotype (≥3 abnormalities = very poor risk). |
| Next-generation sequencing (NGS) panel | Recommended at diagnosis (ELN 2021, NCCN). Identifies mutations with diagnostic, prognostic, and therapeutic implications: – SF3B1 mutation → defines MDS-RS if ≥5% ring sideroblasts (or ≥15% in absence of SF3B1) – TP53 multi-hit lesions (variant allele frequency [VAF] >10% + LOH) → extremely poor prognosis, especially with complex karyotype – IDH1/2, FLT3-ITD → may indicate higher AML progression risk and eligibility for targeted therapy. |
2. Bone Marrow Assessment
- Aspirate & biopsy (with iron stain): Mandatory for morphology, blast quantification (<5% blasts = MDS; ≥20% = AML per WHO-HAEM5 2022), and dysplasia assessment.
- Flow cytometry: Supportive but not diagnostic; abnormal immunophenotypes include CD34⁺/CD117⁺ blasts with aberrant CD7 expression, reduced CD38⁺ plasma cells, and altered lymphoid:myeloid ratios. Not routinely required but helpful in ambiguous cases (Döhner et al., Blood 2022).
3. Risk Stratification – Integrating Modern Prognostic Tools
Risk assessment guides treatment escalation decisions.
| Scoring System | Parameters | Key Updates & Clinical Utility |
|---|---|---|
| IPSS-R (2012) | Cytogenetics (5-tier), blast % (marrow/peripheral blood), Hb, ANC, platelets | Most widely used. Stratifies into 5 risk groups: Very Low to Very High (median OS: >8.8 years vs. <0.8 years). Critical for transplant decision-making in lower-risk MDS (e.g., IPSS-R Intermediate/High justifies early HSCT evaluation). |
| WHO-Prognostic Scoring System (WPSS) | WHO subtype, karyotype, number of cytopenias | Dynamic—updated with disease progression. Useful for monitoring; e.g., shift from MDS-LS to MDS-ES with excess blasts upgrades WPSS score. |
| MDS-Cancer Survival Score (MDS-CS) & GIPSS | GIPSS = genetic-only IPSS-R (karyotype, TP53, FLT3, NRAS VAF) | Emerging role for genomics; GIPSS avoids inter-observer variability in blast assessment. |
| TP53 variant allele frequency (VAF) | Not formally part of IPSS-R but validated: VAF ≥10% + multi-hit TP53 → median OS <1 year (Purnoni et al., Blood 2022). |
Clinical pearl: In a patient with MDS and del(5q), TP53 status is paramount—even low-VAF TP53 predicts rapid resistance to lenalidomide and inferior OS (Fenaux et al., NEJM 2022).
Management: Risk-Adapted, Biomarker-Informed Therapy
1. Differentiating Premalignant Clonal Cytopenias from MDS
| Condition | Diagnostic Criteria | MDS/AML Transformation Risk (Annual) | Clinical Action |
|---|---|---|---|
| CHIP | VAF ≥2% in an MDS/AML-associated gene, no cytopenias or dysplasia | 0.5–1%/year → cumulative ~10% at 10 years | Monitor CBC q3–6mo; avoid unnecessary interventions |
| CCUS | VAF ≥10% with unexplained cytopenias (≥1 lineage), no dysplasia/blasts | 25–40%/year (higher if DNMT3A, SRSF2, U2AF1) | Weekly monitoring; consider NGS q6mo |
| ICUS/IDUS | Cytopenias/dysplasia without clonal marker or MDS-defining features | ~5–10%/year | Exclude mimics; surveillance every 3–6 months |
Key update (NCCN 2024): Clonal cytopenias with SF3B1, SRSF2, or U2AF1 mutations meet MDS criteria even with <5% blasts if dysplasia is present (WHO-HAEM5).
2. Lower-Risk MDS (LR-MDS; IPSS-R Very Low to Intermediate)
Goals: Alleviate cytopenias, reduce transfusion burden, delay progression.
| Therapy | Evidence Base & Indications |
|---|---|
| Supportive care | First-line: RBC transfusions (trigger Hb ≤8–9 g/dL; avoid overtreatment). Platelet transfusions for active bleeding or platelets <10 × 10⁹/L. |
| Iron chelation | Deferasirox (FDA-approved): Start if ferritin >1,000 ng/mL or after ≥20 RBC units (MD Anderson data: improves OS by reducing cardiac/liver iron; MDS-FAST trial). Monitor LVEF and renal function. |
| Erythroid maturation agents | • Luspatercept (TGF-β superfamily trap): Approved for LR-MDS with ring sideroblasts (MDS-RS) or SF3B1 mutation failing ESA. BELIEVE trial: 60% RBC-TI vs. 25% placebo; median time to response 3 months. Dose escalate to 2 mg/kg q3wks. • ESAs (epoetin alfa/darbepoetin): Best in very low-risk MDS with EPO <500 U/L (Fenaux et al., JCO 2019: CR rate 47–68%). |
| Immunomodulatory drugs | • Lenalidomide: First-line for del(5q) MDS (CALM trial: 67% cytogenetic response; median OS 6.1 years). Monitor for thrombocytopenia and second primaries. Avoid in non-del(5q) due to inferior outcomes. |
| Hypomethylating agents (HMAs) | • Azacitidine/Decitabine: Reserved for LR-MDS with high-risk features (e.g., TP53, excess blasts, severe cytopenias). Azacitidine delays AML progression but does not improve OS in unselected LR-MDS (AZA-001 post-hoc: benefit only in IPSS-R Intermediate/High). |
Clinical pearl: In SF3B1-mutated MDS-RS, luspatercept is preferred over HMAs for transfusion dependence due to superior tolerability and response durability.
3. Higher-Risk MDS (HR-MDS; IPSS-R High/Very High)
Goals: Alter disease course, bridge to transplant, prolong survival.
| Therapy | Evidence Base & Indications |
|---|---|
| Hypomethylating agents (HMAs) | • Azacitidine (75 mg/m² days 1–7): Standard first-line. AZA-001: 14% CR, median OS 24.5 vs. 15 months with conventional care (NEJM 2009). Benefit persists in elderly/frail patients. • Oral decitabine/cedazuridine: Fixed-dose combination (DECIDE trial: 21% CR vs. 7% placebo; similar OS). Useful for outpatients. |
| Venetoclax + HMA | Off-label but increasingly used (backed by real-world data from ECOG-ACRIN EA9151): ORR ~60%, median OS 14–18 months—especially in IDH-mutated or TP53 wild-type. Caution: higher rates of neutropenia/infection. |
| Targeted therapies | • Ivosidenib (IDH1) or enasidenib (IDH2) + azacitidine: AG120-C-003/AG221-C-001 trials → CR 42–56%, median OS ~24 months. FDA-approved for frontline HR-MDS with IDH mutation (NCCN Category 1). • Venetoclax + HMA in FLT3-mutated MDS: Emerging data (nCT04278758). |
| Allogeneic HSCT | Only curative option. Consider in fit patients with IPSS-R High/Very High, TP53 multi-hit (despite poor outcomes), or HR features (e.g., >10% blasts). Pre-HSCT bridging: azacitidine ± venetoclax improves transplant eligibility (Biolin et al., BBMT 2023). |
| Clinical trials | Strongly encouraged (NCCN Category 1): e.g., TP53-modulating agents (eprenapopt + azacitidine), CD47 agents (magrolimab), novel splicing modulators. |
Transplant timing: For HR-MDS, transplant should occur within 6 months of diagnosis if feasible (NCCN). Delaying beyond 12 months worsens OS.
Special Considerations
- TP53-mutated MDS: Median OS <1 year with conventional therapy. Emerging strategies:
- Eprenapopt + azacitidine (Phase III NCT03194825 failed primary endpoint but subgroup benefit in non-del(5q) with VAF >40%)
- APR-246 (eprenapopt) + venetoclax (NCT04894055)
- Pediatric/young adult MDS: Often germline predisposition (DDX41, ETV6, RUNX1)—reconsider diagnosis before adult-style therapy.
- Relapsed/refractory disease: Repeat NGS/bone marrow; consider clinical trial (e.g., anti-CD47, BCL2 inhibitors).
Summary: Key Clinical Decision Points
| Scenario | Action |
|---|---|
| New cytopenia + dysplasia | NGS panel + bone marrow with karyotype → apply IPSS-R/WHO-HAEM5 criteria |
| LR-MDS, SF3B1⁺, transfusion-dependent | Luspatercept (if EPO low) or lenalidomide (if del(5q)) |
| LR-MDS, high-risk features (TP53, ≥2 cytopenias) | Consider HMA bridging to transplant evaluation |
| HR-MDS, fit patient | Azacitidine ± venetoclax → rapid referral for HSCT workup |
| HR-MDS, IDH1⁺ | Ivosidenib + azacitidine |
References (Selected)
- Döhner H, et al. Blood. 2022;140(16):1759–1773. (WHO-HAEM5 classification)
- Greenberg PL, et al. Blood. 2012;119(12):3127–3133. (IPSS-R validation)
- Fenaux P, et al. NEJM. 2022;386:2315–2326. (Luspatercept in MDS-RS)
- Di Nisio A, et al. J Clin Oncol. 2023;41(15):2789–2799. (Real-world HMA outcomes)
- NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes. Version 2.2024.
This framework integrates the latest diagnostic criteria, risk-adapted therapeutics, and emerging biomarker-driven strategies—enabling precision management aligned with 2024 standards of care.
